SCHEMBL31235367

SCHEMBL31235367

CC(C)(C)OC(=O)NCC1(CO)COC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR2 O43614 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
GAA P10253 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
EPHX1 P07099 2/20 0.36
NAMPT P43490 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
CTSD P07339 1/20 0.34
CTSL P07711 1/20 0.34
CTSB P07858 1/20 0.34
CTSS P25774 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL510027 0.85 TDP1 (0.46) HCRTR2TDP1GAAMEN1KMT2A
SCHEMBL12598205 0.84 HCRTR2 (0.44) HCRTR2TDP1GAAMEN1KMT2A
SCHEMBL15931187 0.84 HCRTR2 (0.41) HCRTR2TDP1GAAMEN1KMT2A
SCHEMBL16520385 0.84 HCRTR2 (0.41) HCRTR2TDP1GAAMEN1KMT2A
SCHEMBL15931189 0.83 HCRTR2 (0.40) HCRTR2TDP1GAAMEN1KMT2A
SCHEMBL12598988 0.82 TDP1 (0.44) HCRTR2TDP1GAAMEN1KMT2A
SCHEMBL7611276 0.82 TDP1 (0.44) HCRTR2TDP1GAAMEN1KMT2A
SCHEMBL30096683 0.81 TDP1 (0.42) HCRTR2TDP1GAAMEN1KMT2A
SCHEMBL21607436 0.81 TDP1 (0.42) HCRTR2TDP1GAAMEN1KMT2A
Hydrochloric Acid SCHEMBL30096699 0.79 TDP1 (0.41) HCRTR2TDP1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024243025-A1 NAPHTHYL-SUBSTITUTED PYRIDO[4,3-D]PYRIMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Ikena Oncology, Inc. (US) 2024-11-28 WO disclosed